Silence Therapeutics (SLN) Operating Margin: 2020-2025
Historic Operating Margin for Silence Therapeutics (SLN) over the last 6 years, with Sep 2025 value amounting to 16,505.66%.
- Silence Therapeutics' Operating Margin fell 1450319.00% to 16,505.66% in Q3 2025 from the same period last year, while for Sep 2025 it was 321.21%, marking a year-over-year increase of 11438.00%. This contributed to the annual value of 146.38% for FY2024, which is 5709.00% up from last year.
- Per Silence Therapeutics' latest filing, its Operating Margin stood at 16,505.66% for Q3 2025, which was down 54.29% from 10,697.77% recorded in Q2 2025.
- Silence Therapeutics' 5-year Operating Margin high stood at 17.20% for Q4 2024, and its period low was 20,006.34% during Q1 2025.
- Moreover, its 3-year median value for Operating Margin was 633.59% (2023), whereas its average is 4,864.42%.
- In the last 5 years, Silence Therapeutics' Operating Margin skyrocketed by 61,639bps in 2024 and then tumbled by 1,997,079bps in 2025.
- Silence Therapeutics' Operating Margin (MRQ) stood at 329.91% in 2021, then surged by 30bps to 230.03% in 2022, then crashed by 175bps to 633.59% in 2023, then surged by 97bps to 17.20% in 2024, then crashed by 95,873bps to 16,505.66% in 2025.
- Its Operating Margin stands at 16,505.66% for Q3 2025, versus 10,697.77% for Q2 2025 and 20,006.34% for Q1 2025.